Spiriva sustains lung function over 4 years

Results of the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial  have shown that Pfizer’s SPIRIVA HandiHaler (tiotropium bromide inhalation powder) sustains improvements in lung function for up to 4 years  in Chronic [...]

Ipratropium use linked to increased cardiovascular deaths

Data published in teh Annals of Internal Medicine show that ipratropium may elevate risk for all-cause and cardiovascular death.

GSK publish series of muscarinic antagonists

GSK have published a series of biphenyl piperazine muscarinic acetylcholine receptor antagonists

Almirall receive $15M milestone from Forest for aclidinium bromide

Almirall has received a 15 million dollar payment from Forest Laboratories in connection with its phase III development of aclidinium bromide, an antimuscarinic for the treatment of COPD (Chronic Obstructive Pulmonary Disease).

GSK initiate Phase I trial of Muscarinic M1 antagonist GSK1034702

GSK have initiated a Phase I trial of Muscarinic M1 antagonist GSK1034702

Phase I data show Theravance LAMA GSK1160724/TD-4208 safe in COPD patients

Theravance have announced Phase 1 data showing its long acting muscarinic antagonist (LAMA), GSK1160724/TD-4208 to be safe and well tolerated in the treatment of chronic obstructive pulmonary disease (COPD). Partner GSK have, however, informed Theravance that it intends to return the LAMA program to Theravance because the current formulation of TD-4208 is incompatible with GSK’s [...]

Theravance annouces positive Phase II results of MABA GSK961081 in COPD

Theravance/GSK have announced positive results from a Phase II study of GSK961081 for the treatment of chronic obstructive pulmonary disease (COPD). The successful achievement of proof-of-concept in the MABA Phase 2 clinical study triggers a milestone payment of $10 million from GSK.

Mithridion commences Phase I Trial of MCD-386 for Alzheimer’s Disease

Mithridion has commenced a Phase I clinical trial of its investigational drug MCD-386 in Alzheimers. MCD-386 appears to activate of muscarinic M1 type receptor subtypes.

Sciele complete Phase III trial of Glycopyrrolate for Moderate-to-Severe Drooling

Sciele Pharma have completed a phase III trial for Glycopyrrolate Liquid for the treatment of chronic, moderate-to-severe drooling in pediatric patients

Lillys long acting injection olanzapine shows similar profile to Zyprexa

Data prsented at the Schizophrenia International Research Society meeting show Lilly’s long acting injection (LAI) formulation of olanzapine to demonstrate similar efficacy and safety to Zyprexa.